Core Viewpoint - OneSpan (OSPN) shares have increased by 11.8% in the past four weeks, closing at $15.17, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $19.33, representing a 27.4% upside [1] Price Targets and Estimates - The average price targets range from a low of $15 to a high of $23, with a standard deviation of $4.04, indicating variability among analysts [2] - The lowest estimate suggests a decline of 1.1%, while the highest estimate indicates a potential upside of 51.6% [2] - Analysts' consensus on price targets should be approached with caution, as their ability to set unbiased targets has been questioned [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about OSPN's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.4%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Implications - OSPN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not reliably indicate the extent of potential gains, they can provide guidance on the direction of price movement [13]

Group 1 - Constellium (CSTM) shares have increased by 38.2% in the past four weeks, closing at $11.04, with a mean price target of $16.60 indicating a potential upside of 50.4% [1] - The average price targets range from a low of $12 to a high of $24, with a standard deviation of $4.77, suggesting variability in analyst estimates [2] - Analysts show strong agreement on CSTM's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for CSTM's current year earnings has increased by 14.6%, with two estimates moving higher and no negative revisions [12] - CSTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Shares of Align Technology (ALGN) have gained 15.8% over the past four weeks to close the last trading session at $177.61, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $233.42 indicates a potential upside of 31.4%.The average comprises 12 short-term price targets ranging from a low of $170 to a high of $275, with a standard deviation of $31.09. While the lowest estimate indic ...

Core Viewpoint - American Well Corporation (AMWL) has seen an 11.8% increase in share price over the past four weeks, closing at $7.31, with a potential upside of 46.5% based on Wall Street analysts' mean price target of $10.71 [1][11]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $2.58, indicating variability among analysts [2]. - The lowest estimate is $7.50, suggesting a 2.6% increase, while the highest estimate predicts a surge of 105.2% to $15 [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about AMWL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - Over the past 30 days, one estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12]. - AMWL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Summit Therapeutics PLC (SMMT) closed the last trading session at $28.02, gaining 61.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $37.38 indicates a 33.4% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $5.71. While the lowest estimate of $30 indicates a 7.1% increase from the current price level, the most optimistic an ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about BigBear.ai Holdings, Inc. (BBAI) .BigBear.ai currently has an average brokerage recommendation ...

Group 1 - RPC shows a noticeable improvement in earnings outlook, making it an attractive investment pick [1] - Analysts are optimistic about RPC's earnings prospects, reflected in the upward trend of estimate revisions [2][3] - The Zacks Rank system indicates RPC has a Zacks Rank 2 (Buy), suggesting strong potential for outperformance [8] Group 2 - Current-quarter earnings estimate is $0.09 per share, a 40% decrease from the previous year, but has seen a 12.5% increase in the last 30 days [6] - For the full year, the earnings estimate is $0.38 per share, an 11.63% decrease from last year, yet the trend remains positive with no negative revisions [7] - RPC's stock has gained 16.2% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [9]

Core Viewpoint - Shift4 Payments (FOUR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that revisions in earnings estimates can lead to significant price changes [4][6]. - Shift4 Payments is projected to earn $5.46 per share for the fiscal year ending December 2025, reflecting a year-over-year increase of 40.4% [8]. Analyst Sentiment and Market Position - Analysts have raised their earnings estimates for Shift4 Payments, with the Zacks Consensus Estimate increasing by 19.7% over the past three months [8]. - The upgrade to Zacks Rank 2 places Shift4 Payments in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10]. Zacks Rating System Overview - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a proven track record of performance, where Zacks Rank 1 stocks have generated an average annual return of +25% since 1988 [7]. - The system maintains a balanced distribution of ratings, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating, while the next 15% receive a 'Buy' rating [9].

Core Viewpoint - GH Research PLC (GHRS) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on earnings estimates, leading to significant stock price movements when estimates are revised [4]. Company Performance and Outlook - The upgrade reflects an improvement in GH Research's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, GH Research is expected to earn -$1.07 per share, a decrease of 42.7% from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for GH Research has increased by 5.5%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - GH Research's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Shares of Apogee Therapeutics Inc. (APGE) have gained 24.1% over the past four weeks to close the last trading session at $40.12, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.88 indicates a potential upside of 134%.The average comprises eight short-term price targets ranging from a low of $78 to a high of $116, with a standard deviation of $11.05. While the lowest estimat ...